放射医学与防护学院学术报告

报告题目：Therapeutic Antibody Development Driven by Innovative Technologies（创新技术驱动治疗性抗体的发展）

报 告 人：罗培志 博士

时 间：2012年11月8日下午2:00

地 点：炳麟图书馆720会议室

医学部放射医学与防护学院

放射医学及交叉学科研究院

摘要： 6 of the top 10 best selling drugs in 2012 in pharmaceutical industry are therapeutic antibodies. We will share some of the fundamental progresses made in the basic research and technology innovation of therapeutic antibody technology that delivers the promise of the magic bullet- a grand vision by the Noble Prize Winner Paul Ehrlich more than a century ago-for the use of antibodies in revolutionizing the therapy for some of the toughest diseases including cancer and autoimmunity. We will focus on the antibody generation and design technology that can be used to tweak antibodies into shapes and functional modalities beyond their natural limits to meet the challenge in developing more specific, safer, more potent therapeutic antibodies with better integration with downstream production and bioprocess development at affordable price.

罗培志（Peter）博士简介

Dr. Peter (Peizhi) Luo is a serial entrepreneur who is passionate for innovative technology and biopharmaceutical product development. He is the core inventor of some key patents and has published some highly cited research articles. He is the founder, chairman and CEO of Adagene, an emerging biopharmaceutical company that is focused on novel antibody technology and product pipeline development and is backed by Fidelity Bioscience (Boston), Fidelity Asia Growth, and Wuxi Apptec Venture.

Following the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics at Merck & Co., Inc. and was responsible for building Merck in-house antibody libraries and engineering platforms as the discovery engine for Merck novel biologics. Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. and played a crucial role in building the Abmaxis management and scientific teams and in shaping its technology and business strategies. Prior to founding Abmaxis, Dr. Luo was the first lead scientist in Xencor in computational protein design and protein laboratory. Dr. Luo did his postdoctoral research in protein folding at Stanford University. He received his PhD in Chemistry from The University of Chicago, a MS degree in Applied Physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and a BS degree in Applied Chemistry from Peking University.

罗培志博士是一位致力于创新型生物技术和生物制药产品开发的连续创业家，拥有多项全球核心生物技术及产品的专利，发表过多篇引用广泛的原创性论文。罗培志博士在斯坦福大学完成了蛋白质折叠的博士后研究工作，并拥有芝加哥大学化学博士学位，中科院高能物理研究所应用物理学硕士学位及北京大学应用化学学士学位。

罗博士现为天演药业的创始人兼总裁，天演药业是一家新兴的生物制药公司， 致力于原创性抗体技术和产品线的开发。 罗博士曾任默克生物制药主任，同时兼任默克全资子公司 Abmaxis 的首席技术长，负责设计及构建默克抗体库和抗体工程平台, 作为创新生物药研发的引擎。在 2006 年默克(Merck & CO)收购Abmaxis 之前，罗博士作为 Abmaxis 创始人、首席技术官、总裁和董事，在公司管理和科研队伍的组建，研发和经营策略的形成中发挥了关键作用。创立Abmaxis 之前罗博士任职于 Xencor， 是该公司在蛋白药物的计算机设计和蛋白实验室的第一位领头科学家。

欢迎广大师生参加！